Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2004

Open Access 01-11-2004 | Research article

Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome

Authors: Joyce Villanueva, Susan Lee, Edward H Giannini, Thomas B Graham, Murray H Passo, Alexandra Filipovich, Alexei A Grom

Published in: Arthritis Research & Therapy | Issue 1/2004

Login to get access

Abstract

Macrophage activation syndrome (MAS) has been reported in association with many rheumatic diseases, most commonly in systemic juvenile rheumatoid arthritis (sJRA). Clinically, MAS is similar to hemophagocytic lymphohistiocytosis (HLH), a genetic disorder with absent or depressed natural killer (NK) function. We have previously reported that, as in HLH, patients with MAS have profoundly decreased NK activity, suggesting that this abnormality might be relevant to the pathogenesis of the syndrome. Here we examined the extent of NK dysfunction across the spectrum of diseases that comprise juvenile rheumatoid arthritis (JRA). Peripheral blood mononuclear cells (PBMC) were collected from patients with pauciarticular (n = 4), polyarticular (n = 16), and systemic (n = 20) forms of JRA. NK cytolytic activity was measured after co-incubation of PBMC with the NK-sensitive K562 cell line. NK cells (CD56+/T cell receptor [TCR]-αβ-), NK T cells (CD56+/TCR-αβ+), and CD8+ T cells were also assessed for perforin and granzyme B expression by flow cytometry. Overall, NK cytolytic activity was significantly lower in patients with sJRA than in other JRA patients and controls. In a subgroup of patients with predominantly sJRA, NK cell activity was profoundly decreased: in 10 of 20 patients with sJRA and in only 1 of 20 patients with other JRA, levels of NK activity were below two standard deviations of pediatric controls (P = 0.002). Some decrease in perforin expression in NK cells and cytotoxic T lymphocytes was seen in patients within each of the JRA groups with no statistically significant differences. There was a profound decrease in the proportion of circulating CD56bright NK cells in three sJRA patients, a pattern similar to that previously observed in MAS and HLH. In conclusion, a subgroup of patients with JRA who have not yet had an episode of MAS showed decreased NK function and an absence of circulating CD56bright population, similar to the abnormalities observed in patients with MAS and HLH. This phenomenon was particularly common in the systemic form of JRA, a clinical entity strongly associated with MAS.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM: Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol. 1993, 11: 451-456.PubMed Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM: Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol. 1993, 11: 451-456.PubMed
2.
go back to reference Athreya BH: Is macrophage activation syndrome a new entity?. Clin Exp Rheumatol. 2002, 20: 121-123.PubMed Athreya BH: Is macrophage activation syndrome a new entity?. Clin Exp Rheumatol. 2002, 20: 121-123.PubMed
3.
go back to reference Grom AA: Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities?. Curr Opin Rheumatol. 2003, 15: 587-590. 10.1097/00002281-200309000-00011.CrossRefPubMed Grom AA: Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities?. Curr Opin Rheumatol. 2003, 15: 587-590. 10.1097/00002281-200309000-00011.CrossRefPubMed
4.
go back to reference Ramanan AV, Schneider R: Macrophage activation syndrome – what's in a name!. J Rheumatol. 2003, 30: 2513-PubMed Ramanan AV, Schneider R: Macrophage activation syndrome – what's in a name!. J Rheumatol. 2003, 30: 2513-PubMed
5.
go back to reference Silverman ED, Miller JJ, Bernstein B, Shafai T: Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr. 1983, 103: 872-876.CrossRefPubMed Silverman ED, Miller JJ, Bernstein B, Shafai T: Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr. 1983, 103: 872-876.CrossRefPubMed
6.
go back to reference De Vere-Tyndall A, Macauley D, Ansell B: Disseminated intravascular coagulation complicating systemic juvenile rheumatoid arthritis ('Still's disease'). Clin Rheumatol. 1983, 2: 415-418.CrossRefPubMed De Vere-Tyndall A, Macauley D, Ansell B: Disseminated intravascular coagulation complicating systemic juvenile rheumatoid arthritis ('Still's disease'). Clin Rheumatol. 1983, 2: 415-418.CrossRefPubMed
7.
go back to reference Hadchouel M, Prieur AM, Griscelli C: Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985, 106: 561-566.CrossRefPubMed Hadchouel M, Prieur AM, Griscelli C: Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985, 106: 561-566.CrossRefPubMed
8.
go back to reference Ravelli A, De Benedetti F, Viola S, Martini A: Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996, 128: 275-278.CrossRefPubMed Ravelli A, De Benedetti F, Viola S, Martini A: Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996, 128: 275-278.CrossRefPubMed
9.
go back to reference Grom AA, Passo M: Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996, 129: 630-632.CrossRefPubMed Grom AA, Passo M: Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996, 129: 630-632.CrossRefPubMed
10.
go back to reference Sawney S, Woo P, Murray K: Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001, 85: 421-426. 10.1136/adc.85.5.421.CrossRef Sawney S, Woo P, Murray K: Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001, 85: 421-426. 10.1136/adc.85.5.421.CrossRef
11.
go back to reference Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prier AM: Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxford). 2001, 40: 1285-1292.CrossRef Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prier AM: Reactive haemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology (Oxford). 2001, 40: 1285-1292.CrossRef
12.
go back to reference Egeler RM, Shapiro R, Loechelt B, Filipovich AH: Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 1996, 18: 340-345. 10.1097/00043426-199611000-00002.CrossRefPubMed Egeler RM, Shapiro R, Loechelt B, Filipovich AH: Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 1996, 18: 340-345. 10.1097/00043426-199611000-00002.CrossRefPubMed
13.
go back to reference Sullivan KE, Delaat CA, Douglas SD, Filipovich AH: Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res. 1998, 44: 465-468.CrossRefPubMed Sullivan KE, Delaat CA, Douglas SD, Filipovich AH: Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res. 1998, 44: 465-468.CrossRefPubMed
14.
go back to reference Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH: Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002, 99: 61-66. 10.1182/blood.V99.1.61.CrossRefPubMed Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH: Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002, 99: 61-66. 10.1182/blood.V99.1.61.CrossRefPubMed
15.
go back to reference Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Saint Basile G, et al: Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999, 286: 1957-1959. 10.1126/science.286.5446.1957.CrossRefPubMed Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Saint Basile G, et al: Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999, 286: 1957-1959. 10.1126/science.286.5446.1957.CrossRefPubMed
16.
go back to reference Stepp SE, Mathew PA, Bennett M, de Saint Basile G, Kumar V: Perforin: more than just an effector molecule. Immunol Today. 2000, 21: 254-256. 10.1016/S0167-5699(00)01622-4.CrossRefPubMed Stepp SE, Mathew PA, Bennett M, de Saint Basile G, Kumar V: Perforin: more than just an effector molecule. Immunol Today. 2000, 21: 254-256. 10.1016/S0167-5699(00)01622-4.CrossRefPubMed
17.
go back to reference Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich AH: Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003, 142: 292-296. 10.1067/mpd.2003.110.CrossRefPubMed Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich AH: Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003, 142: 292-296. 10.1067/mpd.2003.110.CrossRefPubMed
18.
go back to reference Cassidy JT, Levinson JKE, Bass JC, Baum J, Brewer EJ, Fink CW, Hanson V, Jacobs JC, Masi AT, Schaller JG: A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum. 1986, 29: 274-281.CrossRefPubMed Cassidy JT, Levinson JKE, Bass JC, Baum J, Brewer EJ, Fink CW, Hanson V, Jacobs JC, Masi AT, Schaller JG: A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum. 1986, 29: 274-281.CrossRefPubMed
19.
go back to reference Cassidy JT, Petty RE: Textbook of Pediatric Rheumatology. 2001, Philadelphia: W.B. Saunders Company, 214-217. Cassidy JT, Petty RE: Textbook of Pediatric Rheumatology. 2001, Philadelphia: W.B. Saunders Company, 214-217.
20.
go back to reference Schneider R, Passo MH: Juvenile rheumatoid arthritis. Rheum Dis Clin North Am. 2002, 28: 503-530. 10.1016/S0889-857X(02)00016-9.CrossRefPubMed Schneider R, Passo MH: Juvenile rheumatoid arthritis. Rheum Dis Clin North Am. 2002, 28: 503-530. 10.1016/S0889-857X(02)00016-9.CrossRefPubMed
21.
go back to reference Molleran Lee S, Villanueva J, Sumegi J, Zhang K, Kogawa K, Davis J, Filipovich AH: Characterization of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet. 2004, 41: 137-144. 10.1136/jmg.2003.013003.CrossRefPubMed Molleran Lee S, Villanueva J, Sumegi J, Zhang K, Kogawa K, Davis J, Filipovich AH: Characterization of diverse PRF1 mutations leading to decreased natural killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet. 2004, 41: 137-144. 10.1136/jmg.2003.013003.CrossRefPubMed
22.
go back to reference Nair MP, Schwartz SA: Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes. J Immunol. 1984, 132: 2876-2882.PubMed Nair MP, Schwartz SA: Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes. J Immunol. 1984, 132: 2876-2882.PubMed
23.
go back to reference Wouters CHP, Ceuppens JL, Stevens EAM: Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002, 20: 239-248.PubMed Wouters CHP, Ceuppens JL, Stevens EAM: Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002, 20: 239-248.PubMed
24.
go back to reference Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer cell subsets. Trends Immunol. 2001, 22: 633-640. 10.1016/S1471-4906(01)02060-9.CrossRefPubMed Cooper MA, Fehniger TA, Caligiuri MA: The biology of human natural killer cell subsets. Trends Immunol. 2001, 22: 633-640. 10.1016/S1471-4906(01)02060-9.CrossRefPubMed
25.
go back to reference Villanueva J, Filipovich A, Lee S, Passo MH, Grom AA: Natural killer cell function and perforin expression in patients with systemic onset juvenile rheumatoid arthritis as compared to macrophage activation syndrome and hemophagocytic lymphohistiocytosis [abstract]. Pediatr Blood Cancer. 2004, 43: 200- Villanueva J, Filipovich A, Lee S, Passo MH, Grom AA: Natural killer cell function and perforin expression in patients with systemic onset juvenile rheumatoid arthritis as compared to macrophage activation syndrome and hemophagocytic lymphohistiocytosis [abstract]. Pediatr Blood Cancer. 2004, 43: 200-
26.
go back to reference Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W: Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003, 42: 375-379.CrossRef Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W: Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003, 42: 375-379.CrossRef
27.
go back to reference Normand NJ, Lehman TJA, Elkon KB, Onel KB: Lower expression of perforin in CD8+ T cells of patients with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000, 43: S406- Normand NJ, Lehman TJA, Elkon KB, Onel KB: Lower expression of perforin in CD8+ T cells of patients with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000, 43: S406-
28.
go back to reference Baxter AG, Smyth MJ: The role of NK cells in autoimmune disease. Autoimmunity. 2002, 35: 1-14. 10.1080/08916930290005864.CrossRefPubMed Baxter AG, Smyth MJ: The role of NK cells in autoimmune disease. Autoimmunity. 2002, 35: 1-14. 10.1080/08916930290005864.CrossRefPubMed
29.
go back to reference Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K, Kawa H, Komiyama A: A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol. 1996, 23: 171-177.PubMed Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K, Kawa H, Komiyama A: A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol. 1996, 23: 171-177.PubMed
30.
go back to reference Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, Dupond JL, Larroche C, Piette AM, Mechenstock D, et al: Reactive hemophagocytic syndrome in adult systemic disease: report of 26 cases and literature review. Arthritis Rheum. 2003, 49: 633-639. 10.1002/art.11368.CrossRefPubMed Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, Dupond JL, Larroche C, Piette AM, Mechenstock D, et al: Reactive hemophagocytic syndrome in adult systemic disease: report of 26 cases and literature review. Arthritis Rheum. 2003, 49: 633-639. 10.1002/art.11368.CrossRefPubMed
31.
go back to reference Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, et al: HLA Class I, NKG2D and natural cytotoxicity receptors regulate mutliple myeloma cell recognition by natural killer cells. Blood. 2004, Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, et al: HLA Class I, NKG2D and natural cytotoxicity receptors regulate mutliple myeloma cell recognition by natural killer cells. Blood. 2004,
32.
go back to reference Arico M, Danesino C, Pende D, Moretta L: Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001, 114: 761-769. 10.1046/j.1365-2141.2001.02936.x.CrossRefPubMed Arico M, Danesino C, Pende D, Moretta L: Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001, 114: 761-769. 10.1046/j.1365-2141.2001.02936.x.CrossRefPubMed
33.
go back to reference Su HC, Nguyen KB, Salazar-Mather TP, Ruzek MC, Dalod MY, Biron CA: NK cell functions restrain T cell resonses during viral infections. Eur J Immunol. 2001, 31: 3048-3055. 10.1002/1521-4141(2001010)31:10<3048::AID-IMMU3048>3.0.CO;2-1.CrossRefPubMed Su HC, Nguyen KB, Salazar-Mather TP, Ruzek MC, Dalod MY, Biron CA: NK cell functions restrain T cell resonses during viral infections. Eur J Immunol. 2001, 31: 3048-3055. 10.1002/1521-4141(2001010)31:10<3048::AID-IMMU3048>3.0.CO;2-1.CrossRefPubMed
34.
go back to reference Spielman J, Lee RK, Podack ER: Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis. J Immunol. 1998, 161: 7063-7070.PubMed Spielman J, Lee RK, Podack ER: Perforin/Fas-ligand double deficiency is associated with macrophage expansion and severe pancreatitis. J Immunol. 1998, 161: 7063-7070.PubMed
35.
go back to reference Matloubian M, Suresh M, Glass A, Galvan M, Chow K, Whitmire JK, Walsh CM, Clark WR, Ahmed R: A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol. 1999, 73: 2527-2536.PubMedCentralPubMed Matloubian M, Suresh M, Glass A, Galvan M, Chow K, Whitmire JK, Walsh CM, Clark WR, Ahmed R: A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol. 1999, 73: 2527-2536.PubMedCentralPubMed
36.
go back to reference Badovinac VP, Tvinnereim AR, Harty JT: Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science. 2000, 290: 1354-1358. 10.1126/science.290.5495.1354.CrossRefPubMed Badovinac VP, Tvinnereim AR, Harty JT: Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science. 2000, 290: 1354-1358. 10.1126/science.290.5495.1354.CrossRefPubMed
37.
go back to reference Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA: NK cell and DC interactions. Trends Immunol. 2004, 25: 47-52. 10.1016/j.it.2003.10.012.CrossRefPubMed Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA: NK cell and DC interactions. Trends Immunol. 2004, 25: 47-52. 10.1016/j.it.2003.10.012.CrossRefPubMed
38.
go back to reference Castriconi R, Della Chiesa M, Morreta A: Shaping of adaptive immunity by innate interactions. C R Biol. 2004, 327: 533-537.CrossRefPubMed Castriconi R, Della Chiesa M, Morreta A: Shaping of adaptive immunity by innate interactions. C R Biol. 2004, 327: 533-537.CrossRefPubMed
Metadata
Title
Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome
Authors
Joyce Villanueva
Susan Lee
Edward H Giannini
Thomas B Graham
Murray H Passo
Alexandra Filipovich
Alexei A Grom
Publication date
01-11-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1453

Other articles of this Issue 1/2004

Arthritis Research & Therapy 1/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.